Adding Darzalex (daratumumab) to the standard first-line treatment of Revlimid (lenalidomide) plus dexamethasone improves treatment and survival outcomes in multiple myeloma patients…
News
CT103A, a fully-human anti-B-cell mature antigen (BCMA) CAR T-cell therapy, leads to strong anti-cancer responses in patients with relapsed or refractory multiple…
Ygalo (melflufen) combination therapy continues to lead to clinically meaningful responses, without significant side effects, in patients with relapsed or refractory multiple…
Interim data from an ongoing Phase 1/2 clinical trial show that Celgene’s investigational therapy iberdomide (CC-220), used in combination with dexamethasone, is safe and…
The investigational immunotherapy AMG 420 lessened tumor burden and led to cancer disappearing in half of the patients with relapsed or refractory multiple…
Isatuximab, a potential therapeutic antibody, can improve survival in relapsed/refractory multiple myeloma patients being given a standard treatment consisting of Pomalyst (pomalidomide) and…
An under-the-skin formulation of daratumumab is as effective as its intravenous delivery — marketed as Darzalex — at easing tumor burden and has comparable…
The U.S. Food and Drug Administration (FDA) has granted Priority Review to the supplemental Biologics License Application (sBLA) of Darzalex (daratumumab)…
The candidate CAR-T cell therapy bb2121 showed a favorable safety profile and eliminated traces…
Treatment with Pomalyst (pomalidomide) in combination with Velcade (bortezomib) and dexamethasone prolongs survival without disease worsening…
